To include your compound in the COVID-19 Resource Center, submit it here.

T-DM1: Phase II data

Top-line data from the open-label, international Phase II TDM4450g trial in 137 treatment-naïve patients with HER2-positive metastatic breast cancer showed that 3.6 mg/kg IV T-DM1 every 3 weeks as first-line therapy met

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE